The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
 
Tanya B. Dorff
Honoraria - Astellas Pharma; Bayer; Medivation; Myriad Genetics; Pfizer; Sanofi
Consulting or Advisory Role - Dendreon; Genentech
Speakers' Bureau - Astellas Pharma; Bayer; Pfizer
Research Funding - Bristol-Myers Squibb
 
Jeff Longmate
No Relationships to Disclose
 
Susan G. Groshen
Employment - Pfizer (I)
 
Walter Michael Stadler
Honoraria - Bayer; CVS Caremark; Johnson & Johnson; medpacto; Merck; Sotio
Consulting or Advisory Role - Bayer; CVS Caremark; Johnson & Johnson; medpacto; Merck; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - UpToDate
 
Mayer N. Fishman
Consulting or Advisory Role - Bayer/Onyx
Speakers' Bureau - GlaxoSmithKline; Prometheus
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Prometheus; TRACON Pharma
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer
 
Jacek K. Pinski
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Janssen; Millennium
Research Funding - Aeterna Zentaris (Inst)
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
James Hu
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Fresenius Kabi; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
Expert Testimony - Medivation; Teva
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; PER; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst); TRACON Pharma (Inst)